What Travere Therapeutics promised, and what happened

Guidance Tracker · every commitment management made on a call, tracked from the quarter it was made

Guidance

What management said, and what became of it

9 of 9 judged targets kept · 8 open · verdicts reflect calls analysed to Jun 2026.

Target	Original wording	Said	Latest call	Verdict
Data readout from post-transplant recurrent FSGS/IgAN study	Anticipate data from this study in 2027	Jun 2026	Jun 2026:We recently completed enrollment in our post-transplant study evaluating recurrent FSGS and recurrent IgA nephropathy, areas of significant unmet need. We anticipate data from this study in 2027. Call transcript, Jun 2026 · no direct link	New
FDA full approval of FILSPARI (sparsentan) in FSGS	Potential full FDA approval for sparsentan in FSGS in 2025 (year-end 2025), contingent on sNDA submission	Sep 2024	Mar 2026:We achieved the first FDA approval in FSGS Call transcript, Mar 2026 · no direct link	Achieved*

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

The full ledger

Open Travere Therapeutics’s full ledger

A free account opens 5 company ledgers a month. All 17 tracked commitments, with each call’s wording and source.

US Pro opens 100 a month, first month free →

The rest of the ledger

Pro opens all 17 tracked commitments for Travere Therapeutics

Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

Upgrade to Pro, one month free